Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.

Yingxin ZhaoPeng ChenDaihong LiuFei LiMeng LiLingmin XuJing ChenMingyu JiaSai HuangNan WangSonghua LuanJinling YangNan BaiDaihong Liu

Published in: Drug design, development and therapy (2022)

Our findings confirmed a moderate inhibitory DDI between ruxolitinib and voriconazole as voriconazole decreased the elimination and increased the exposure of ruxolitinib in patients with hematologic malignancies. We recommended a dose reduction regimen when voriconazole and ruxolitinib were coadministered. Drug monitoring might help determine the ruxolitinib treatment concentration for aGVHD patients, improve efficacy, and reduce toxicity.

Keyphrases

end stage renal disease
newly diagnosed
oxidative stress
peritoneal dialysis
high intensity
patient reported outcomes